These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12236793)

  • 1. Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor.
    Learmonth DA; Freitas AP
    Bioconjug Chem; 2002; 13(5):1112-8. PubMed ID: 12236793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor.
    Palma PN; Bonifácio MJ; Loureiro AI; Wright LC; Learmonth DA; Soares-da-Silva P
    Drug Metab Dispos; 2003 Mar; 31(3):250-8. PubMed ID: 12584150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
    Soares-da-Silva P; Vieira-Coelho MA; Parada A
    Pharmacol Toxicol; 2003 Jun; 92(6):272-8. PubMed ID: 12787259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, reduces the peripheral O-methylation of L-DOPA and enhances its availability to the brain.
    Parada A; Soares-da-Silva P
    Pharmacology; 2003 May; 68(1):29-37. PubMed ID: 12660477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.
    Kiss LE; Ferreira HS; Torrão L; Bonifácio MJ; Palma PN; Soares-da-Silva P; Learmonth DA
    J Med Chem; 2010 Apr; 53(8):3396-411. PubMed ID: 20334432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase.
    Learmonth DA; Bonifácio MJ; Soares-da-Silva P
    J Med Chem; 2005 Dec; 48(25):8070-8. PubMed ID: 16335931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application.
    Bonifácio MJ; Archer M; Rodrigues ML; Matias PM; Learmonth DA; Carrondo MA; Soares-Da-Silva P
    Mol Pharmacol; 2002 Oct; 62(4):795-805. PubMed ID: 12237326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase.
    Learmonth DA; Vieira-Coelho MA; Benes J; Alves PC; Borges N; Freitas AP; da-Silva PS
    J Med Chem; 2002 Jan; 45(3):685-95. PubMed ID: 11806720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
    Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
    Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor.
    Tsuji E; Okazaki K; Takeda K
    Biochem Biophys Res Commun; 2009 Jan; 378(3):494-7. PubMed ID: 19056347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
    Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
    Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J
    Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.
    Bonifati V; Meco G
    Pharmacol Ther; 1999 Jan; 81(1):1-36. PubMed ID: 10051176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal Structure of Catechol O-Methyltransferase Complexed with Nitecapone.
    Iijima H; Takebe K; Suzuki M; Kobayashi H; Takamiya T; Saito H; Niwa N; Kuwada-Kusunose T
    Chem Pharm Bull (Tokyo); 2020; 68(5):447-451. PubMed ID: 32378542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor.
    Bonifácio MJ; Vieira-Coelho MA; Soares-da-Silva P
    Eur J Pharmacol; 2003 Jan; 460(2-3):163-70. PubMed ID: 12559377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of Catechol-O-Methyltransferase.
    Barrow JC
    CNS Neurol Disord Drug Targets; 2012 May; 11(3):324-32. PubMed ID: 22483290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase.
    de Beer J; Petzer JP; Lourens ACU; Petzer A
    Mol Divers; 2021 May; 25(2):753-762. PubMed ID: 32108308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors.
    Bäckström R; Honkanen E; Pippuri A; Kairisalo P; Pystynen J; Heinola K; Nissinen E; Linden IB; Männistö PT; Kaakkola S
    J Med Chem; 1989 Apr; 32(4):841-6. PubMed ID: 2704029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity.
    Lerner C; Masjost B; Ruf A; Gramlich V; Jakob-Roetne R; Zürcher G; Borroni E; Diederich F
    Org Biomol Chem; 2003 Jan; 1(1):42-9. PubMed ID: 12929389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.